Craig Feaster, MD
Child & Adolescent Psychiatry · State College, PANPI 1912905795
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,980 of the $18,288 with a category attached, or 60.0%. Corium, LLC accounts for 77.6% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $10,567 and has fallen 86.2% since, to $1,455 in 2025. Among child & adolescent psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $70.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$14K
- Supernus Pharmaceuticals, Inc.$743
- Otsuka America Pharmaceutical, Inc.$642
- Johnson & Johnson$501
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$491
- Alkermes, Inc.$399
- plus $1K from 18 others
What the payments were for
- Consulting fees$2,44013%
- Speaking & faculty fees$10,98060%
- Travel & lodging$1901%
- Food & beverage$4,67726%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,288 in reported general payments places this provider in the 95th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.
See all child & adolescent psychiatry providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 20 | $55,843 |
| VraylarCariprazine Hcl | 16 | $24,845 |
| QelbreeViloxazine Hcl | 14 | $8,565 |
| AzstarysSerdexmethylphen/Dexmethylphen | 19 | $7,613 |
| TrintellixVortioxetine Hydrobromide | 17 | $7,594 |
| IntunivGuanfacine Hcl | 13 | $3,824 |
| Haloperidol | 101 | $2,961 |
| Atomoxetine Hcl | 45 | $2,793 |
| Guanfacine Hcl | 95 | $2,674 |
| Aripiprazole | 84 | $1,731 |
| Lamotrigine | 157 | $1,368 |
| Clomipramine Hcl | 17 | $1,332 |
| Prazosin Hcl | 66 | $994 |
| Oxcarbazepine | 17 | $977 |
| Bupropion XlBupropion Hcl | 31 | $959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $642 | $55,84320 claims |
| AbbVieVraylar | $221 | $24,84516 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $743 | $8,56514 claims |
| Corium, LLCAzstarys | $14,193 | $7,61319 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $33 | $7,59417 claims |
| Shire North American Group IncIntuniv | $38 | $3,82413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.
Other child & adolescent psychiatry in State College
- Mukundam VeerabathiniState College$8K
- Dennis BorczonErie$120K
- Suzanne LucotCranberry Township$72K
- Dan UdreaWexford$51K
- Robert WilsonErie$34K
- Thomas WindPhiladelphia$17K
- Laura AdangPhiladelphia$15K
- Christoph LamPhiladelphia$13K
- Raman BawejaHershey$11K
- Jeffrey HermannYork$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.